Stiefel a GSK company: Following the ISISTM premise, we continue to provide support in the development of primary and supporting publications showcasing the value of new therapeutic formulations for the management of acne.
Spondylitis Association of America: Because of our intimate knowledge of rheumatologic conditions, we have lent our support to the SAA through ongoing consultation and by providing the design and execution of ISISTM-inspired communication plans and educational outreach programs. We are immensely proud to support such a dedicated organization that provides never-ending support to its members and their families.
LifeCell Corporation: Developed and executed a scientific communications plan built on the ISISTM platform to showcase the value of a novel surgical device to gastric surgeons.
Johnson & Johnson Consumer Products: Through ISISTM, Medisys continues to communicate among the dermatology community the data-driven science behind the Active Naturals® in the AVEENO® product lines by developing and executing scientifically rigorous programs.
Janssen: Taking a wide body of seemingly disparate information, ISISTM defined the targets, needs, and solutions of several medical specialties on the early identification and management of pediatric neurological disorders.
Ortho Dermatologics: Through ISISTM, Medisys continues to communicate the data-driven science behind the organization’s medical therapeutics.
International Psoriasis Council: We know dermatology. Leveraging our knowledge, we take great pride in designing, developing and executing, multi-purpose gatherings of board member, physician members, staff, external experts, and corporate members to discuss ongoing business matters, hold scientific sessions, produce enduring materials, and ultimately advance the understanding and treatment of psoriasis.
Baxter International: Using ISISTM, we are working closely with a multidisciplinary team within Baxter to develop a global scientific communications platform to support the launch of an innovative new product for the treatment of primary immunodeficiency diseases.
Centocor Research & Development, Inc.: Under the banner of ISISTM, we continue to drive the scientific communications platforms for several biologic agents as they extend their therapeutic reach into new disease areas.
Galderma: Coupling ISISTM with our profound knowledge of the dermatology landscape, we set the stage for the successful launch of products for rosacea, psoriasis and acne.
Janssen-Cilag: ISISTM, along with our universal presence in the dermatologic and rheumatologic fields, gave us the opportunity to design and execute a scientific communications platform that set the stage for the company’s first European launch of a novel biologic agent for the management of psoriasis.
Acclarent, Inc.: Designed a mini-scientific communications plan targeting the primary care community that showcased the value of a novel medical procedure for chronic sinusitis and thereby the value of the company prior to acquisition.
McNeil Consumer & Specialty Pharmaceuticals: Our core strength of moving consumer products beyond consumer marketing using ISISTM was founded on the development of unique programs in the areas of scalp infections, fever in children, and acute pain.